{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=97&state=Georgia",
    "query": {
      "state": "Georgia",
      "city": "Atlanta",
      "page": 97
    },
    "page_size": 10
  },
  "pagination": {
    "page": 97,
    "page_size": 10,
    "total_count": 13090,
    "total_pages": 1309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=98&state=Georgia&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=96&state=Georgia&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T17:41:11.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00198289",
      "title": "Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "Aurexis® (tefibazumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2005-04",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198289"
    },
    {
      "nct_id": "NCT01033825",
      "title": "Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Perennial Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Ciclesonide HFA Nasal Aerosol 320 mcg",
          "type": "DRUG"
        },
        {
          "name": "Ciclesonide HFA Nasal Aerosol 160 mcg",
          "type": "DRUG"
        },
        {
          "name": "HFA Nasal Aerosol placebo",
          "type": "DRUG"
        },
        {
          "name": "Ciclesonide Aqueous Nasal Spray 200 mcg",
          "type": "DRUG"
        },
        {
          "name": "AQ Nasal Spray Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus Dexamethasone HFA",
          "type": "DRUG"
        },
        {
          "name": "Placebo AQ plus Dexamethasone 6 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2010-01",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-07-19",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 6,
      "location_summary": "Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Minneappolis",
          "state": "Minnesota"
        },
        {
          "city": "Skillman",
          "state": "New Jersey"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01033825"
    },
    {
      "nct_id": "NCT03264989",
      "title": "Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 57,
      "start_date": "2017-12-19",
      "completion_date": "2023-06-26",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 12,
      "location_summary": "Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03264989"
    },
    {
      "nct_id": "NCT01781468",
      "title": "Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "armodafinil 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "armodafinil 250 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2013-06-21",
      "completion_date": "2019-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 365,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781468"
    },
    {
      "nct_id": "NCT02952989",
      "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Renal Cell",
        "Breast Neoplasms",
        "Urinary Bladder Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Colorectal Neoplasms",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "SGN-2FF",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-02-23",
      "completion_date": "2019-06-24",
      "has_results": false,
      "last_update_posted_date": "2019-07-19",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952989"
    },
    {
      "nct_id": "NCT00006268",
      "title": "Immunotoxin Therapy in Treating Patients With Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "cintredekin besudotox",
          "type": "BIOLOGICAL"
        },
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "New Approaches to Brain Tumor Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-10",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006268"
    },
    {
      "nct_id": "NCT01374490",
      "title": "Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Enteropathy",
        "Diarrhea With HIV"
      ],
      "interventions": [
        {
          "name": "Crofelemer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2011-06-07",
      "completion_date": "2012-10-31",
      "has_results": true,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01374490"
    },
    {
      "nct_id": "NCT04599855",
      "title": "A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Esketamine 56 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 84 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 477,
      "start_date": "2020-11-04",
      "completion_date": "2024-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04599855"
    },
    {
      "nct_id": "NCT05181540",
      "title": "A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AB-205",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Angiocrine Bioscience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-02-21",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 28,
      "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181540"
    },
    {
      "nct_id": "NCT04241068",
      "title": "A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Aducanumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 1696,
      "start_date": "2020-03-02",
      "completion_date": "2024-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-22T17:41:11.224Z",
      "location_count": 104,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04241068"
    }
  ]
}